Related Experiment Videos
Selective 5-HT2C agonists as potential antidepressants
1Department of Medicinal Chemistry, Scientific Development Group, NV Organon, 5340 BH Oss, The Netherlands. d.leysen@organon.oss.akzonobel.nl
Idrugs : the Investigational Drugs Journal
|September 15, 2005
Summary
Selective serotonin 5-HT2C agonists show promise as novel antidepressants. These compounds demonstrate improved efficacy and tolerability compared to existing treatments, potentially benefiting depression and related disorders.
Area of Science:
- Neuroscience
- Pharmacology
- Psychiatry
Background:
- Current antidepressants have limitations in efficacy, relapse rates, and speed of action.
- There is a need for improved therapeutic options for depression and related psychiatric conditions.
Purpose of the Study:
- To review clinical and experimental data supporting the use of 5-HT2C agonists for depression.
- To summarize results from non-selective and selective 5-HT2C agonists in preclinical and clinical development.
Main Methods:
- Review of clinical and experimental data on 5-HT2C agonists.
- Analysis of results from marketed and investigational non-selective 5-HT2C agonists.
- Summary of preclinical data for selective 5-HT2C agonists.
Main Results:
- Preclinical data suggest selective 5-HT2C agonists possess greater potency and effect size than fluoxetine.
- These selective agonists demonstrate good tolerability and no signs of tolerance development.
- Non-selective agonists currently available and in development are also described.
Conclusions:
- Selective 5-HT2C agonists represent a potential new class of innovative drugs for treating depression.
- These agents may also be effective for panic disorder, obsessive-compulsive disorder (OCD), aggression, and eating disorders.